Cellectis S.A. (Nasdaq: CLLS) filed a Form 6-K to disclose outcomes of its 26 June 2025 Combined General Meeting of Shareholders and subsequent Board re-composition. The filing formally incorporates the voting tally (Exhibit 99.1) and the accompanying press release (Exhibit 99.2) into several active U.S. shelf and equity compensation registration statements. Board and Audit Committee changes : Shareholders elected André Muller to the Board with immediate effect. Concurrently, the mandate of Axel-Sven Malkomes lapsed and the previously announced resignation of Pierre Bastid became effective. Following these departures, the Board re-constituted its Audit Committee, naming Mr. Muller as Chair alongside Donald Bergstrom and Rainer Boehm. The company states that all three members meet both Nasdaq Global Market and SEC Rule 10A-3 independence criteria, ensuring continued compliance with U.S. listing requirements.